A A vaccine is under investigation for salmonella It received promising results in phase II clinical trials on humans, with no safety issues noted.
This is the CVD 1902 serum, which specifically protects against Parathyphi serotype bacteria. salmonella enterica, Which causes danger Paratyphoid fever.
Study characteristics
Specifically, the developers implemented Phase 2b clinical trialAs stated in the study published on this topic in the academic journal new england journal of medicine, On 72 healthy adults with an average age of 32 years and no history of enteric fever.
These volunteers were also recruited Two 30 mL doses of CVD1902 were given 14 days apart Or placebo in the same way.
About 28 days after the second dose, participants were exposed to the bacteria using an oral solution to evaluate the condition Development of infection Or its absence (based on a blood test or the presence of a fever of at least 38°C for at least twelve hours) as well as various immunological markers such as type G and A (IgG and IGA) antibody responses against flagellin and lipopolysaccharide O antigens 14 and 42 days after the first dose.
73% efficacy and good safety profile
In this way, they found that while 75% of patients treated with placebo developed infection, this only occurred in 21% of those vaccinated, which is consistent with Vaccine effectiveness 73%. Antibody levels in vaccinated volunteers increased significantly after the first dose of the vaccine, while they remained the same at baseline in those who did not receive the serum.
next to, No adverse event was recorded that were considered to be related to the vaccine or placebo, which represents the good safety profile of the serum.
More studies (especially phase III clinical trials) still need to be done for this to work Vaccine approved for clinical useBut for now, these results represent valuable evidence of its effectiveness and safety.
References
Naina McCann, Margaret Paganotti Visentin, Narges Ebrahimi, Melanie Greenland, Brian Angus, Andrea M. Collins, Thomas Darton and others. Safety, efficacy, and immunogenicity of Salmonella paratifi A vaccine. New England Journal of Medicine (2025). doi: 10.1056/NEJMoa2502992
Want the best content to take care of your health and feel good? Subscribe to our newsletter for free.
We are already on WhatsApp! If you want to get the latest news and top stories of the day on your mobile phone, Click here and join our channel. It is a free, convenient and secure system.
About The Author
